Ketamine Nasal Spray Approved as Standalone Treatment for Tough Depression Cases
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other options.
Inquirer on MSN2d
Controlled drug Ketamine a lifeline for patients with severe depression in S’poreKetamine therapy is now a mainstream prescription for treatment-resistant depression. Read more at straitstimes.com.
The Dell Inspiron 15 has some fairly robust specs. At its heart, the Intel i5-1235U processor with 10 cores and up to 4.40 ...
Better book a session with your therapist — yet another painful consequence of your parents’ divorce has emerged.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback